7 completed. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 1 | Completed 1 |
Follow Vaccine Reaction: new trials by email Literature Review of Vaccine Reaction trials Research Report on Vaccine Reaction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved. Regimen 1, Regimen 2 - Vaccine Reaction | Phase 3 | Completed | Kempegowda Institute of Medical Sciences, Bangalore | 144 | 2023-04-03 | 2026-08-07 |
| Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants Eupolio - Poliomyelitis, Vaccine Reaction | Phase 3 | Completed | LG Chem | 2001 | 2023-01-10 | 2025-04-06 |
| Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Completed | PT Bio Farma | 1050 | 2022-10-09 | 2025-06-03 |
| A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Grippol Quadrivalent, Grippol Plus - Influenza, Influenza A | Phase 3 | Completed | NPO Petrovax | 824 | 2022-09-21 | 2024-04-26 |
| One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. MTX-hold - Rheumatoid Arthritis, Autoimmune Diseases | Phase 3 | Completed | Seoul National University Hospital | 184 | 2021-10-01 | 2022-12-16 |
| Allergy and COVID-19 Vaccines COVID-19 Vaccines - Anaphylactic Reaction, Vaccine Reaction | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 117 | 2021-09-15 | 2026-09-17 |
| Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine Influenza vaccine [inactivated] - Influenza, Influenza, Human | Phase 2 / Phase 3 | Completed | St. Petersburg Research Institute of Vaccines and Sera | 450 | 2020-10-06 | 2023-05-22 |
Influenza, Human (3) · Anaphylaxis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Infections (1) · Orthomyxoviridae Infections (1) · Poliomyelitis (1)
RNA Virus Infections (4) · Virus Diseases (4) · Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Immune System Diseases (2) · Orthomyxoviridae Infections (2) · Arthritis (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Connective Tissue Diseases (1) · Enterovirus Infections (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Joint Diseases (1)
2019-nCoV Vaccine mRNA-1273 (1) · COVID-19 Vaccines (1) · Grippol (1) · Influenza Vaccines (1)
Assistance Publique - Hôpitaux de Paris (1) · Kempegowda Institute of Medical Sciences, Bangalore (1) · LG Chem (1) · NPO Petrovax (1) · PT Bio Farma (1) · Seoul National University Hospital (1) · St. Petersburg Research Institute of Vaccines and Sera (1)
Russia (2) · France (1) · India (1) · Indonesia (1) · Philippines (1) · South Korea (1) · Thailand (1)
Asrawati Asrawati, MD (1) · Bernie Medise, MD (1) · Cahya Satria, MD (1) · Deekshith J Reddy, MBBS (1) · Ellina Ruzanova (1)
PMID 28468794, PMID 29572291, PMID 31823141, PMID 35216744, PMID 35930728, PMID 36249342, PMID 36971457